1.-.-.- Oxidoreductases
Unless otherwise stated all data on this page refer to the human proteins. Gene information is provided for human (Hs), mouse (Mm) and rat (Rn).
Enzymes
Targets of relevance to immunopharmacology are highlighted in blue
|
aldehyde dehydrogenase 2 family member
Show summary »« Hide summary
More detailed page
|
|||||||||||||||||||||||||||
|
aldo-keto reductase family 1 member B
Show summary »« Hide summary
More detailed page
|
|||||||||||||||||||||||||||
|
VAP-1 (amine oxidase copper containing 3)
Show summary »« Hide summary
More detailed page
|
|||||||||||||||||||||||||||
|
catalase C
Show summary »« Hide summary
More detailed page
|
|||||||||||||||||||||||||||
|
DHFR (dihydrofolate reductase)
C
Show summary »« Hide summary
More detailed page
|
|||||||||||||||||||||||||||
|
DHODH (dihydroorotate dehydrogenase (quinone))
C
Show summary »« Hide summary
More detailed page
|
|||||||||||||||||||||||||||
|
glutathione-disulfide reductase
Show summary »« Hide summary
More detailed page
|
|||||||||||||||||||||||||||
|
hydroxy-delta-5-steroid dehydrogenase, 3 beta- and steroid delta-isomerase 2
Show summary »« Hide summary
More detailed page
|
|||||||||||||||||||||||||||
|
4-hydroxyphenylpyruvate dioxygenase
Show summary »« Hide summary
More detailed page
|
|||||||||||||||||||||||||||
|
11-βHSD1 (hydroxysteroid 11-beta dehydrogenase 1)
Show summary »« Hide summary
More detailed page
|
|||||||||||||||||||||||||||
|
11-βHSD2 (hydroxysteroid 11-beta dehydrogenase 2)
Show summary »« Hide summary
More detailed page
|
|||||||||||||||||||||||||||
|
hydroxysteroid 17-beta dehydrogenase 2
Show summary »« Hide summary
More detailed page
|
|||||||||||||||||||||||||||
|
hydroxysteroid 17-beta dehydrogenase 13 Show summary »« Hide summary
|
|||||||||||||||||||||||||||
|
IMPDH1 (inosine monophosphate dehydrogenase 1) C
Show summary »« Hide summary
More detailed page
|
|||||||||||||||||||||||||||
|
IMPDH2 (inosine monophosphate dehydrogenase 2) C
Show summary »« Hide summary
More detailed page
|
|||||||||||||||||||||||||||
|
myeloperoxidase
Show summary »« Hide summary
More detailed page
|
|||||||||||||||||||||||||||
|
sepiapterin reductase
Show summary »« Hide summary
More detailed page
|
|||||||||||||||||||||||||||
|
steroid 5 alpha-reductase 2
Show summary »« Hide summary
More detailed page
|
|||||||||||||||||||||||||||
|
tyrosinase
Show summary »« Hide summary
More detailed page
|
|||||||||||||||||||||||||||
|
vitamin K epoxide reductase complex subunit 1
Show summary »« Hide summary
More detailed page
|
|||||||||||||||||||||||||||
|
XDH (xanthine dehydrogenase) C
Show summary »« Hide summary
More detailed page
|
|||||||||||||||||||||||||||
References
1. Bevans CG, Krettler C, Reinhart C, Tran H, Koßmann K, Watzka M, Oldenburg J. (2013) Determination of the warfarin inhibition constant Ki for vitamin K 2,3-epoxide reductase complex subunit-1 (VKORC1) using an in vitro DTT-driven assay. Biochim Biophys Acta, 1830 (8): 4202-10. [PMID:23618698]
2. Evenäs J, Edfeldt F, Lepistö M, Svitacheva N, Synnergren A, Lundquist B, Gränse M, Rönnholm A, Varga M, Wright J et al.. (2014) HTS followed by NMR based counterscreening. Discovery and optimization of pyrimidones as reversible and competitive inhibitors of xanthine oxidase. Bioorg Med Chem Lett, 24 (5): 1315-21. [PMID:24508129]
3. FIELD JB, GOLDFARB MS, WARE AG, GRIFFITH GC. (1952) Effect in man of a new indandione anticoagulant. Proc Soc Exp Biol Med, 81 (3): 678-81. [PMID:13037763]
4. Heikkilä T, Ramsey C, Davies M, Galtier C, Stead AM, Johnson AP, Fishwick CW, Boa AN, McConkey GA. (2007) Design and synthesis of potent inhibitors of the malaria parasite dihydroorotate dehydrogenase. J Med Chem, 50 (2): 186-91. [PMID:17228860]
5. Hollman A. (1991) Dicoumarol and warfarin. Br Heart J, 66 (2): 181. [PMID:18610395]
6. Keller C, Matzdorff AC, Kemkes-Matthes B. (1999) Pharmacology of warfarin and clinical implications. Semin Thromb Hemost, 25 (1): 13-6. [PMID:10327215]
7. Liu X, Sturla SJ. (2009) Profiling patterns of glutathione reductase inhibition by the natural product illudin S and its acylfulvene analogues. Mol Biosyst, 5 (9): 1013-24. [PMID:19668867]
8. Lowe ED, Gao GY, Johnson LN, Keung WM. (2008) Structure of daidzin, a naturally occurring anti-alcohol-addiction agent, in complex with human mitochondrial aldehyde dehydrogenase. J Med Chem, 51 (15): 4482-7. [PMID:18613661]
9. Nelson PH, Eugui E, Wang CC, Allison AC. (1990) Synthesis and immunosuppressive activity of some side-chain variants of mycophenolic acid. J Med Chem, 33 (2): 833-8. [PMID:1967654]
10. Nurminen EM, Pihlavisto M, Lázár L, Szakonyi Z, Pentikäinen U, Fülöp F, Pentikäinen OT. (2010) Synthesis, in vitro activity, and three-dimensional quantitative structure-activity relationship of novel hydrazine inhibitors of human vascular adhesion protein-1. J Med Chem, 53 (17): 6301-15. [PMID:20690686]
11. Rabe T, Kiesel L, Kellermann J, Weidenhammer K, Runnebaum B, Potts GO. (1983) Inhibition of human placental progesterone synthesis and aromatase activity by synthetic steroidogenic inhibitors in vitro. Fertil Steril, 39 (6): 829-35. [PMID:6574022]
12. Rosowsky A, Mota CE, Queener SF, Waltham M, Ercikan-Abali E, Bertino JR. (1995) 2,4-Diamino-5-substituted-quinazolines as inhibitors of a human dihydrofolate reductase with a site-directed mutation at position 22 and of the dihydrofolate reductases from Pneumocystis carinii and Toxoplasma gondii. J Med Chem, 38 (5): 745-52. [PMID:7877140]
13. Schilter HC, Collison A, Russo RC, Foot JS, Yow TT, Vieira AT, Tavares LD, Mattes J, Teixeira MM, Jarolimek W. (2015) Effects of an anti-inflammatory VAP-1/SSAO inhibitor, PXS-4728A, on pulmonary neutrophil migration. Respir Res, 16: 42. [PMID:25889951]
14. Singh SB, Malamas MS, Hohman TC, Nilakantan R, Carper DA, Kitchen D. (2000) Molecular modeling of the aldose reductase-inhibitor complex based on the X-ray crystal structure and studies with single-site-directed mutants. J Med Chem, 43 (6): 1062-70. [PMID:10737739]
15. Smith DJ, Vainio P, Mikkola J, Vuorio P, Vainio J. (2011) Fully human anti-VAP-1 monoclonal antibodies. Patent number: US7897149 B2. Assignee: Biotie Therapies Corp.. Priority date: 20/04/2007. Publication date: 01/03/2011.
16. Tajima R, Oozeki H, Muraoka S, Tanaka S, Motegi Y, Nihei H, Yamada Y, Masuoka N, Nihei K. (2011) Synthesis and evaluation of bibenzyl glycosides as potent tyrosinase inhibitors. Eur J Med Chem, 46 (4): 1374-81. [PMID:21334791]
17. Thamm S, Willwacher MK, Aspnes GE, Bretschneider T, Brown NF, Buschbom-Helmke S, Fox T, Gargano EM, Grabowski D, Hoenke C et al.. (2023) Discovery of a Novel Potent and Selective HSD17B13 Inhibitor, BI-3231, a Well-Characterized Chemical Probe Available for Open Science. J Med Chem, 66 (4): 2832-2850. [PMID:36727857]
18. TOOHEY M. (1952) Antagonism of anticoagulants dicoumarol, tromexan, and phenylindandione by vitamin K. Br Med J, 2 (4786): 687-90. [PMID:12978288]
19. Wallin R, Wajih N, Hutson SM. (2008) VKORC1: a warfarin-sensitive enzyme in vitamin K metabolism and biosynthesis of vitamin K-dependent blood coagulation factors. Vitam Horm, 78: 227-46. [PMID:18374197]
20. Zhang R, Piao MJ, Oh MC, Park JE, Shilnikova K, Moon YJ, Kim DH, Jung U, Kim IG, Hyun JW. (2016) Protective Effect of an Isoflavone, Tectorigenin, Against Oxidative Stress-induced Cell Death via Catalase Activation. J Cancer Prev, 21 (4): 257-263. [PMID:28053960]
How to cite this family page
Database page citation:
1.-.-.- Oxidoreductases. Accessed on 19/04/2024. IUPHAR/BPS Guide to PHARMACOLOGY, http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=840.
Concise Guide to PHARMACOLOGY citation:
Alexander SPH, Fabbro D, Kelly E, Mathie AA, Peters JA, Veale EL, Armstrong JF, Faccenda E, Harding SD, Davies JA et al. (2023) The Concise Guide to PHARMACOLOGY 2023/24: Enzymes. Br J Pharmacol. 180 Suppl 2:S289-373.
This work is licensed under a Creative Commons Attribution-ShareAlike 4.0 International License